Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct;37(4):426-429.
doi: 10.1055/s-0040-1715869. Epub 2020 Oct 1.

Hypersensitivity Reaction after Transarterial Chemoembolization

Murad M Alqadi  1 , Shadab Khan  1 , Ali Kord  1 , Ketan Y Shah  1 , Ron C Gaba  1
Affiliations
Review

Hypersensitivity Reaction after Transarterial Chemoembolization

Murad M Alqadi et al. Semin Intervent Radiol. 2020 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures not related to this work: Ron C. Gaba receives research support from Guerbet USA LLC, Janssen Research & Development LLC, the United States Department of Defense, and the United States National Institutes of Health. He serves as a consultant for Sus Clinicals, Inc.

Figures

Fig. 1
Fig. 1
Contrast-enhanced abdominal MRI scan displays multifocal liver masses with imaging features diagnostic of hepatocellular carcinoma; right hepatic lobe index tumor demarcated by arrows.
Fig. 2
Fig. 2
Pre–transarterial chemoembolization digital subtraction arteriography reveals mild hypervascularity of the right hepatic lobe liver tumor (arrows).
Fig. 3
Fig. 3
Fluoroscopic spot image obtained after conventional transarterial chemoembolization shows deposition of high attenuation chemotherapy emulsion within right liver lobe tumor (arrows).
Fig. 4
Fig. 4
Postembolization digital subtraction arteriography demonstrates residual right hepatic lobe vascular supply to tumor (arrows).
Fig. 5
Fig. 5
Digital subtraction arteriography depicts persistent right hepatic lobe tumor enhancement (arrows).
See this image and copyright information in PMC

References

    1. Clark T W. Complications of hepatic chemoembolization. Semin Intervent Radiol. 2006;23(02):119–125. - PMC - PubMed
    1. Tu J, Jia Z, Ying X. The incidence and outcome of major complication following conventional TAE/TACE for hepatocellular carcinoma. Medicine (Baltimore) 2016;95(49):e5606. - PMC - PubMed
    1. Society of Interventional Radiology Standards of Practice Committee . Gaba R C, Lokken R P, Hickey R M. Quality improvement guidelines for transarterial chemoembolization and embolization of hepatic malignancy. J Vasc Interv Radiol. 2017;28(09):1210–1.223E6. - PubMed
    1. Kawaoka T, Aikata H, Katamura Y. Hypersensitivity reactions to transcatheter chemoembolization with cisplatin and Lipiodol suspension for unresectable hepatocellular carcinoma. J Vasc Interv Radiol. 2010;21(08):1219–1225. - PubMed
    1. Pagani M.The complex clinical picture of presumably allergic side effects to cytostatic drugs: symptoms, pathomechanism, reexposure, and desensitization Med Clin North Am 20109404835–852., xiii - PubMed